5 May 2025 | ACB News – Sydney，ImpediMed Limited (ASX: IPD), a leading Australian medical technology company, has reported record results for the third quarter of FY2025, ended 31 March. Key financial metrics reached new highs as the company continues to scale deployment of its SOZO® digital health platform in the U.S.
■ Record Revenue, Growing Recurring Income, and Strengthened Customer Base
Q3 revenue rose to A$3.4 million, up 28% year-on-year, with record customer receipts of A$4.1 million. Core Annual Recurring Revenue (ARR) reached A$13.7 million, up 10% from the previous quarter and 27% from a year earlier.
Total Contracted Value (TCV) signed in the quarter was A$4.9 million, a 53% increase from Q2. The company noted a 19% average price uplift on contract renewals, including across NCCN centers and large integrated delivery networks (IDNs) in the U.S. ImpediMed’s cash balance stood at A$27.9 million, equivalent to 8.1 quarters of operating runway, following a US$10 million drawdown from its US$15 million growth facility.
■ Sales Acceleration and Clinical Expansion
ImpediMed identified over 500 new sales leads during the quarter—a record for the company—driven by increased marketing and conference engagement, including its debut at the Oncology Nursing Society (ONS) annual meeting. With new SVP of Sales Scott Long now leading the team, focus has shifted to conversion and scaling deployments across 28 U.S. IDNs with existing MSAs.
Meanwhile, the SOZO Pro device is undergoing clinical trials in heart failure and other new indications. The platform remains the only FDA-cleared BIS-based system included in NCCN guidelines for lymphoedema screening.
■ Supply Chain Strategy and Share Price Rebound
To ensure supply continuity, ImpediMed will make a one-time payment of A$1.2 million in Q4 to procure critical components at pre-tariff prices. FY25 operating costs are projected to be 10% lower than FY24, reflecting ongoing cost discipline.
On the market front, shares rebounded last week after retesting the A$0.03 level, a key low first established in 2020, reaching an intraday high of A$0.042 on increased trading volume. Investors are watching to see whether the price base can support a sustained recovery.
■ Outlook: Fundamentals Align with Market Interest
Looking ahead, several factors may influence valuation:
Continued ARR growth and renewal pricing gains
Execution of U.S. commercial rollout
Clinical progress in heart failure and other indications
Strong cash position supporting expansion
A potential re-rating if operational progress and share price recovery converge
